The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase 2 study of cabozantinib (Cabo) combined with ipilimumab (Ipi)/nivolumab (Nivo) and transarterial chemoembolization (TACE) in patients with liver limited unresectable hepatocellular carcinoma (uHCC).
 
Farshid Dayyani
Consulting or Advisory Role - AstraZeneca; Eisai; Jazz Pharmaceuticals
Speakers' Bureau - Astellas Pharma; beone; ipsen; Sirtex Medical; Takeda
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Exelixis (Inst); Genentech (Inst); Ipsen (Inst); Merck (Inst); Taiho Pharmaceutical (Inst)
 
Jennifer Valerin
Consulting or Advisory Role - AstraZeneca; Myriad Genetics
Speakers' Bureau - AstraZeneca; Incyte
 
Dayantha Fernando
No Relationships to Disclose
 
Christina Boyd
No Relationships to Disclose
 
Kristen Neumann
No Relationships to Disclose
 
David Imagawa
No Relationships to Disclose
 
Zeljka Jutric
No Relationships to Disclose
 
Reed Ayabe
Consulting or Advisory Role - Applied Medical
Patents, Royalties, Other Intellectual Property - International Patent WO2023096651A1 Methods for Treating Bile Duct Cancers with Tivozanib
Travel, Accommodations, Expenses - Intuitive Surgical
 
Adam Burgoyne
No Relationships to Disclose
 
Thomas Taylor
No Relationships to Disclose
 
Jasmine Balangue
No Relationships to Disclose
 
Fa-Chyi Lee
No Relationships to Disclose
 
May Cho
Employment - Replimune
Consulting or Advisory Role - Amgen; Astellas Pharma; AstraZeneca; Basilea; BeiGene; Eisai; Exelixis; Genentech/Roche; Ipsen; QED Therapeutics; Seagen; Taiho Pharmaceutical
Speakers' Bureau - Bristol-Myers Squibb/Celgene; Daiichi Sankyo/Astra Zeneca; Helsinn Therapeutics; natera; Pfizer; Taiho Pharmaceutical
Research Funding - AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Immunocore (Inst); incyte (Inst); Seagen (Inst)
Travel, Accommodations, Expenses - AstraZeneca/MedImmune; Seagen
 
April Choi
No Relationships to Disclose
 
Nadine Abi-Jaoudeh
Consulting or Advisory Role - Ask Biomedical; AstraZeneca; Boston Scientific; Eisai; Genentech/Roche; Guerbet; Guerbet; Histosonics; InstyllaHES; IVQIA Inc; RenovoRx; Replimune; Sirtex Medical; TERUMO; Varian Medical Systems
Speakers' Bureau - AngioDynamics Inc
Research Funding - ABK Y90 (Inst); BlackSwan Vascular (Inst); Guerbet (Inst); Impact Biotech Inc (Inst); Innova Vascular (Inst); Instylla (Inst); Medtronic (Inst); Penumbra (Inst); Sirtex Medical (Inst); Teclison (Inst); Varian Medical Systems (Inst)